Free Trial
OTCMKTS:UCBJY

UCB (UCBJY) Stock Price, News & Analysis

UCB logo
$88.29 +0.63 (+0.72%)
As of 04:00 PM Eastern

About UCB Stock (OTCMKTS:UCBJY)

Key Stats

Today's Range
$87.92
$88.50
50-Day Range
$75.96
$96.96
52-Week Range
$68.25
$106.60
Volume
25,089 shs
Average Volume
48,018 shs
Market Capitalization
$33.38 billion
P/E Ratio
N/A
Dividend Yield
0.54%
Price Target
N/A
Consensus Rating
N/A

Company Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Receive UCBJY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJY Stock News Headlines

UCB SA (UCBJY)
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
See More Headlines

UCBJY Stock Analysis - Frequently Asked Questions

UCB's stock was trading at $98.85 on January 1st, 2025. Since then, UCBJY shares have decreased by 10.7% and is now trading at $88.29.
View the best growth stocks for 2025 here
.

Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Ex-Dividend for 5/14 Dividend
4/28/2025
Record date for 5/14 Dividend
4/29/2025
Dividend Payable
5/14/2025
Today
5/29/2025
Next Earnings (Estimated)
7/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:UCBJY
Previous Symbol
OTCMKTS:UCBJY
Employees
9,083
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
34.51
P/E Growth
0.69
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.27 billion
Cash Flow
$3.67 per share
Price / Cash Flow
23.88
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$33.14 billion
Optionable
Not Optionable
Beta
0.54

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:UCBJY) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners